奈沙加群
|
|
- CAS号:
- 159668-20-9
- 英文名:
- Napsagatran
- 英文别名:
- Napsagatran;Ro 46-6240 hydrate;Napsagatran (hydrate);Ro 46-6240/010 hydrate;Napsagatran [usan:inn]
- 中文名:
- 奈沙加群
- 中文别名:
- 奈沙加群;奈沙加群水合物;化合物 T16273
- CBNumber:
- CB01402328
- 分子式:
- C26H36N6O7S
- 分子量:
- 576.67
- MOL File:
- 159668-20-9.mol
|
|
|
奈沙加群化学性质
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
Soluble in DMSO
-
|
奈沙加群性质、用途与生产工艺
Napsagatran hydrate 是一种新型的特异性凝血酶 (thrombin) 抑制剂。
Napsagatran (Ro 46-6240), the selective thrombin inhibitor, induces a dose-dependent prolongation of the activated partial thromboplastin time (aPTT) and prothrombin time (PT) that is evident 15 min after administration of the bolus of Napsagatran. Napsagatran also reduces the time to reperfusion in a dose-dependent manner and delays or prevents reocclusion. The decreasing intracellular amount and efflux of compound from the cells into the medium is measured. The measured CL
int,efflux
values are 0.13±0.06, 3.2±0.6, 10.1±2.3, and 110±2.8 for Digoxin, Fexofenadine, Napsagatran, and Rosuvastatin, respectively, thus representing drugs with a >800-fold range of efflux rates.
After the first hour of drug administration (from 0 to 60 min), the incorporated radioactivity into thrombi increased from baseline by 73±13, 67±22 and 32±10% in placebo, AP-1 and Napsagatran-treated rabbits, respectively. Statistical analysis confirm that thrombus growth in the placebo and AP-1 treated rabbits is not different. In contrast, reduction of
125
I-fibrinogen incorporation by Napsagatran is statistical different from the placebo group (P<0.01).
奈沙加群
上下游产品信息
上游原料
下游产品
159668-20-9, 奈沙加群 相关搜索:
- 化合物 T16273
- 奈沙加群水合物
- 奈沙加群
- 159668-20-9
- Ro 46-6240/010 hydrate
- Ro 46-6240 hydrate
- Napsagatran (hydrate)
- Napsagatran [usan:inn]
- Napsagatran